Scholars Central

Case reportPublished 2019

A Rare Case OF HER 2 Amplified and MET Mutated Metastatic Gastric Cancer with Clinical Benefit to MET Inhibition: A Case Report

Authors: Dr. Joydeep Ghosh

Journal of Integrative Oncology

Volume 8 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The treatment of metastatic stomach cancer has evolved over the last few years. Presently, the most common chemotherapy regimen comprises of Fluorouracil and platinum-based combinations. In the case of HER 2 positive disease, the treatment involves a combination of chemotherapy with trastuzumab. However, there have been cases of resistance to the above combination. Multiple underlying molecular mechanisms have been postulated for the resistance. One of the commonest pathways is CMET mutation. However, the presence of C MET and HER 2 is very rare. Here, we present such a rare case of metastatic stomach cancer who had abnormalities in both the pathways leading to resistance to Trastuzumab.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Integrative Oncology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Integrative Oncology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Dr. Joydeep Ghosh”